Jpmorgan Chase & CO Cin Cor Pharma, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$10.75 - $29.84 $66,832 - $185,515	6,217 Added 3.23%	198,946 $2.45 Million
Q3 2022 Nov 14, 2022	SELL	$19.9 - $38.94 $32,158 - $62,927	-1,616 Reduced 0.83%	192,729 $6.33 Million
Q2 2022 Aug 11, 2022	BUY	$13.67 - $25.74 $2.58 Million - $4.86 Million	188,904 Added 3471.86%	194,345 $3.66 Million
Q1 2022 May 11, 2022	BUY	$14.13 - $28.49 $76,881 - $155,014	5,441 New	5,441 $95,000

Ticker CINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,764,300
Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.